MASH affects over 250 million globally, with advanced cases expected to double by 2030 due to underlying conditions like obesity and metabolic syndrome. Recent FDA and EMA approvals of Rezdiffra and ...

The MarketWatch News Department was not involved in the creation of this content. -- Secondary analyses of the ESSENCE trial were presented at the American Association for the Study of Liver Diseases ...

If you have heart issues, such as high blood pressure or high cholesterol, taking steps to manage them helps keep your heart health in check. But it also helps prevent comorbidities (other conditions ...

Fatty liver disease happens when too much fat builds up in the liver. Metabolic dysfunction-associated steatohepatitis (MASH) is a severe type of fatty liver disease where fat buildup causes liver ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

If you have diabetes, you probably know the condition is linked to a greater risk of several health problems, including heart disease, kidney disease, nerve damage, and more. But one risk you may not ...

MASH prevalence is projected to remain under 5% by 2040, with new treatments like resmetirom now available. Diagnostic challenges and underestimation in claims data affect accurate prevalence ...

Metabolic dysfunction-associated steatohepatitis (MASH) starts in your liver, but it can have body-wide effects. These effects increase your risk of conditions like heart disease, chronic kidney ...

Any discussion of what British food is — or at least was — must have at its heart the pie and mash shop (or “eel and pie house” as they were originally known). This sentiment is no truer than during ...